期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
卷 5, 期 6, 页码 1512-1516出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2017.04.024
关键词
Chronic rhinosinusitis; Nasal polyps; Endotype; Type 2 inflammation; Biomarkers; Biologics; Omalizumab; Mepolizumab; Dupilumab
资金
- Seventh EU Framework program [260895]
- Flemish Scientific Research Board, FWO [1841713N, G.039412N, G.067512N]
- Ghent University [BOF14/GOA/019, BOF01J01113, BOF 14-GOA-019]
In western countries, 85% of chronic rhinosinusitis with nasal polyp disease reveals a type 2 inflammatory pattern with expression of IL-4, -5, and -13 as well as increased concentrations of IgE, whereas chronic rhinosinusitis without nasal polyps merely expresses these biomarkers. The degree of type 2 inflammation furthermore is associated with disease severity, asthma comorbidity, and recurrence of disease after surgery. Therefore, these biomarkers also form the targets for innovative therapeutic approaches such as monoclonal antibodies directed against IgE, IL-5, and IL-4 receptor alpha, blocking the activity of IL-4 and -13. Having demonstrated efficacy in severe asthma, the antibodies have been tested in proof-of-concept studies in patients with nasal polyposis with or without asthma, and have demonstrated their potential to reduce nasal and sinus nasal polyp burden monitored by nasal endoscopy and computed tomography scanning, and to improve typical symptoms. No biomarkers have been identified to select subjects for therapy, to predict response to a specific drug, or to monitor treatment success, which is best documented by nasal polyp score and symptoms. Phase 3 studies are currently in preparation or running, which aim to demonstrate efficacy in larger patient populations and to achieve registration for the indication nasal polyps. (C) 2017 American Academy of Allergy, Asthma & Immunology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据